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Abstract
A 75-year-old male presented with lower back pain, bilateral lower extremity weakness, decreased sensation to vibration and proprioception in lower extremities, anemia, and vitamin B12 deﬁciency. The MRI of the lumbar spine
revealed extensive leptomeningeal carcinomatosis. Subsequently, the patient was diagnosed with multiple myeloma
(MM) and B12 deﬁciency with negative intrinsic factor antibodies. MM can present as extramedullary hematopoiesis
(EM) to involve the central nervous system (CNS). CNS involvement is rare and develops in only around 1% of MM
patients. It carries a poor prognosis with less than 6 months survival. MM is thought to be associated with both B12
deﬁciency and pernicious anemia. Some studies have even suggested B12 deﬁciency as a possible marker for worsening
disease and a prognostic factor. In our patient's case, he had extensive CNS involvement at diagnosis of MM with very
low B12 levels. The extent of his disease with extensive CNS involvement, which carries a poor prognosis, could
possibly explain the very low levels of B12. This is the ﬁrst reported case of a patient presenting with B12 deﬁciency
found to have MM with leptomeningeal carcinomatosis at diagnosis. To the author's knowledge, there is no literature
investigating association between B12 deﬁciency at the time of diagnosis of MM with CNS complications. Furthermore,
there are no established guidelines on treatment for leptomeningeal myelomatosis. We present this case with the effort
to learn more about this disease in terms of response and overall survival.
Keywords: Multiple myeloma, Vitamin B12, Vitamin B12 deﬁciency, CNS involvement, Leptomeningeal myelomatosis,
Leptomeningeal carcinomatosis

1. Introduction

M

ultiple Myeloma (MM) is a hematological
neoplasm that constitutes about 1.6% of cancer cases reported in the United states and is associated with increased morbidity and mortality.1 MM
is mainly a disease of the elderly with median age
above 65 and is characterized by proliferation and
inﬁltration of the bone marrow with clonal plasma
cells and increase of abnormal monoclonal immunoglobulins in the serum or urine.2 The clinical
presentation and evaluation consist of non-speciﬁc
symptoms of bone pain, weight loss, fatigue/
generalized weakness while others may present
with hypercalcemia, anemia, proteinuria, and renal

involvement.1 Multiple myeloma can present as
discrete masses of monoclonal neoplastic plasma
cells in bone, solid tissues, or central nervous system (CNS). This extramedullary myeloma (EM) is
seen when plasma cells escape the bone marrow
and inﬁltrate other tissues. There have been reports
of skin, liver, pancreas, lungs, lymph nodes, and
central nervous system involvement.2 EM of CNS
type is a more aggressive subtype of multiple
myeloma with an unrelenting course and with poor
prognosis with survival typically being less than 6
months. CNS involvement, presenting as either
dural myeloma, intra parenchymal inﬁltration or
leptomeningeal lesions, is rare and develops in only
around 1% of MM patients.2 In patients with CNS
involvement symptoms may include focal
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neurological deﬁcits, impaired mental state, or
cognitive disability.2 There has been literature suggesting that low vitamin B12 levels may represent
prognostic signiﬁcance and could function as a
marker for worsening MM when CNS involvement
has not yet been identiﬁed.
We report a 75-year-old male with history significant for sick sinus syndrome and hepatitis C who
presented to the emergency department (ED) with
bilateral lower extremity weakness of 6 months in
duration. Patient was found to have MM (IgG
Kappa) with leptomeningeal involvement presenting with B12 deﬁciency. There are no established
guidelines on treatment for leptomeningeal myelomatosis. We present this case with the effort to learn
more about this disease in terms of response and
overall survival.

2. Case presentation
We report a case of a 75-year-old African American male with past medical history of Hepatitis C
and sick sinus syndrome status post pacemaker
placement who presented with progressively worsening bilateral lower extremity weakness of six
months in duration. He states that his bilateral
lower extremity weakness is associated with intermittent numbness causing unsteady gait, incurring
frequent falls. Patient reported borrowing lower
back pain that radiates down the back of his legs
along with 40 pounds of weight loss. He denied any
urinary or bowel incontinence, night sweat, fevers,
chills, dizziness, headaches, blurry vision, shortness
of breath, nausea, vomiting, any recent travels or
sick contacts, syncope, seizures, speech changes.
Patient is independent with all activities of daily
living at his baseline. Patient has no history of
alcohol or tobacco use disorder and no family history of malignancy, liver, or kidney disease.
On the physical exam the patient appeared frail
and cachectic and in mild distress due to his lower
back pain. His muscle strength was decreased at a
three on a 5-point scale in bilateral lower extremities
with diminished sensation to vibration, temperature, and light touch. There was no hepatosplenomegaly or lymphadenopathy detected. On
the initial basic metabolic panel, the patient had a
protein gap of 7.8 g/dL, with albumin 2.9 g/dL, total
protein 10.7 g/dL, BUN 16 mg/dL, and creatinine
1.09 mg/dL. His folate level was 16 ng/dL and
vitamin B12 124 pg/mL. Patient's complete blood
count was signiﬁcant for macrocytic anemia with
hemoglobin 8.9 g/dL, hematocrit 26.8 g/dL, mean
corpuscular volume (MCV) 101.5 fL, Red cell distribution width (RDW) 13.4%, platelets 166,000 mm3,

white blood cells 5.5  103/mm3 with an absolute
neutrophil count (ANC) 3.71  103/mm3. His anemia
proﬁle revealed iron 94 mcg/dL, TIBC 234 mcg/dL,
Ferritin 327 ng/mL, erythrocyte sedimentation rate
(ESR) 70 mm/h. A complete pernicious anemia work
up was done that was unremarkable. Patient was
treated for vitamin b12 deﬁciency.
On magnetic resolution imaging (MRI) of the
lumbar spine demonstrated a pathological fracture
at the level of L5 vertebral body. There was a lesion
in the left L1 vertebral body extending into the
pedicle and a left L3 vertebral body lesion with
enhancement. There was a nodular enhancement
along the conus medullaris in the leptomeninges
compatible with leptomeningeal carcinomatosis.
There was a fusiform mass along the right L3-4
neural foramen, along the bilateral L4-5 neural foramen, bilateral L5-S1 neural foramen and along the
S1 to S3 neural foramina bilaterally with enhancement. There was also an enhancement along the
T12-L1, L1-2 and L2-3 neural foramen. A compression fracture of L5 was noted leading to marked
central stenosis with lateral recess stenosis bilaterally. A computed tomography (CT) scan of the head/
brain was unremarkable. A CT scan of the chest,
abdomen, and pelvis was unremarkable, without
any evidence of adenopathy, ascites, or inﬂammatory changes (see Fig. 1).
There were concerns for Multiple Myeloma (MM)
and further workup was undertaken. Patient's labs
revealed a monoclonal gammopathy with IgG
7113 mg/dL, IgM <20 mg/dL, IgA 33 mg/dL, M
spike 5.7 g/dL, beta-2 microglobulin 2.5 mg/L, free
kappa light chains 416.3 mg/L, with a kappa/lambda
ratio 154 (normal: 0.26e1.65), with an LDH 109 unit/
L, and uric acid 4.7 mg/dL.
Immunoﬁxation showed IgG monoclonal protein
with kappa light chain speciﬁcity. The bone marrow
aspirate smears showed markedly increased plasma
cells, focally approximately 79% of the total number
of cells, consistent with plasma cell myeloma. The
ﬂow cytometry analysis demonstrated monoclonal
IgG kappa plasma cells. The Fluorescence in-situ
hybridization (FISH) conﬁrmed Multiple Myeloma
and the cytogenetic analysis showed no evidence of
chromosomal abnormalities.
Taken together with the laboratory ﬁndings,
physical examination, imaging along with the bone
marrow pathology report, the patient was diagnosed
with advanced multiple myeloma with an initial
presentation of vitamin b12 deﬁciency and CNS
involvement manifesting in gait abnormalities.
There are studies that have shown a correlation
between vitamin b12 deﬁciency and multiple
myeloma as a marker of disease severity. Our case is
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Fig. 1. There is heterogeneity of marrow signal with multiple foci of STIR hyperintensity and enhancement compatible with diffuse osseous metastases
(yellow arrow). There is a probable pathologic compression fracture of the L5 vertebral body with concavity of the superior and inferior endplates and
marrow edema (green arrow). There is nodular enhancement along the conus medullaris in the leptomeninges compatible with leptomeningeal
carcinomatosis (red arrow). There is a fusiform mass along the right L3-4 neural foramen, along the bilateral L4-5 neural foramen, bilateral L5-S1
neural foramen and along the S1 to S3 neural foramen bilaterally with enhancement (red arrow). There is also enhancement along the T12-L1, L1-2
and L2-3 neural foramen.

unique in that the patient presented with intramedullary lesions in the central nervous system
(CNS) as an extremely rare complication of multiple
myeloma in the setting of vitamin b12 deﬁciency.

3. Discussion
Multiple myeloma (MM) is a bone marrowderived clonal plasma cell neoplasm that is

characterized by the overproduction of monoclonal
antibodies.3 MM is a devastating disease where
patients may develop renal failure, cytopenia, infections because of immunoparesis, electrolyte abnormalities like hypercalcemia, and lytic bone
lesions manifesting as skeletal symptoms with back
pain and vertebral fractures.4 Extramedullary
dissemination, a rare event, has also been noted
with MM and carries a poor prognosis. Among the
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locations for extramedullary hematopoiesis, the
central nervous system (CNS) involvement is
particularly devastating with an even worse prognosis.5 MM involving the CNS is a rare complication
of MM occurring in roughly 1% of MM patients with
an overall survival of less than 6 months.5 Based on
a review by Dispenzieri and Kyle, intracranial
plasmacytomas or myelomas can be classiﬁed into
four groups:1 lesions extending from the skull and
pressing inward,2 lesions growing from the dura
mater or the leptomeninges,3 lesions from the mucous membranes of a nasopharyngeal plasmacytoma, and4 intraparenchymal lesions not arising
from any of these other sites.6 Leptomeningeal
involvement is the most common form, often leading to nerve root inﬁltration and cerebral nerve
palsies.6 Leptomeningeal metastasis can be diagnosed by either magnetic resonance imaging (MRI)
and/or evidence of malignant cells in CSF cytology.6
Vitamin B12 deﬁciency has been associated with
MM through various postulated mechanisms that
are still not completely understood.7,8 Some of the
mechanisms of B12 deﬁciency described are development of speciﬁc autoantibodies, possible IgM
paraprotein with inherent anti-intrinsic-factor-like
activity, or renal dysfunction hindering appropriate
B12 absorption.3 Pernicious anemia has been associated with IgG and IgM kappa type of paraproteinemia
along
with
IgA
myeloma.3
Furthermore, Seegobin et al. described worsening of
MM in association with B12 deﬁciency and pernicious anemia. They found worsening pancytopenia
along with increasing monoclonal paraprotein
levels with a simultaneous decrease in B12 levels.3
They concluded that B12 deﬁciency could possibly
behave as a marker of worsening MM and overall
disease activity. Yikilmaz et al. retrospectively
investigated an association between B12 deﬁciency
and MM and concluded that vitamin B12 may carry
prognostic signiﬁcance in disease course. They
recorded B12 levels at diagnosis of MM along with
complications such as hypercalcemia and fracture.4
They found B12 deﬁciency in approximately 20% of
patients with MM at the time of diagnosis which
correlated with an increased frequency of hypercalcemia and bone fracture.4
This is the ﬁrst reported case of a patient presenting
with B12 deﬁciency found to have MM with leptomeningeal involvement. His lower back pain with
gait abnormalities due to decreased sensation of vibration and proprioception, prompted checking
folate and B12 levels along with imaging by MRI of the
thoracic and lumbar spine. His B12 levels were

signiﬁcantly low at 126 mg/dL. The imaging revealed
leptomeningeal carcinomatosis and diffuse vertebral
osteolytic lesions. Patient's labs were concerning for
renal failure and pancytopenia. Our patient's work-up
for pernicious anemia was unremarkable. Taken
together these ﬁndings prompted MM work-up that
conﬁrmed the diagnosis. This patient's presentation
poses a unique scenario of differentiating whether the
neurological symptoms were due to the B12 deﬁciency, leptomeningeal involvement, or a combination of both. It will be imperative to follow the patient
to assess for symptom resolution status post B12
supplementation or whether his symptoms continue
until he is treated for leptomeningeal carcinomatosis.
In retrospect, this corroborates the ﬁnding that
low levels of vitamin B12 may help indicate the
disease severity. The question becomes if B12 deﬁciency was predictive of this patient's advanced
disease with CNS involvement or if the two factors
were an independent and rare combination. The
previous studies and cases reported with MM and
CNS involvement did not report B12 deﬁciencies. It
is unclear whether these patient's B12 levels were
measured. To the author's knowledge, there is no
literature investigating association between B12
deﬁciency at the time of diagnosis of MM with CNS
complications of leptomeningeal carcinomatosis.
Further investigation and research into the relationship between B12 deﬁciency and CNS involvement in MM is needed to demonstrate the
usefulness of B12 levels as a marker for worsening
MM, disease activity, and/or a prognostic factor.

4. Conclusion
Multiple myeloma is an incurable neoplasm of
monoclonal plasma cells that makes up approximately 1.6% of cancer cases. MM can have extramedullary involvement and rarely can occur in the
CNS, manifesting as leptomeningeal carcinomatosis. The prognosis is extremely poor with overall
survival being less than 6 months. Furthermore,
there may be an association between MM and
vitamin B12 levels. Patients with vitamin B12 deﬁciency at diagnosis of MM may serve as a prognostic
factor or a marker for worsening disease as our
patient was then found to have CNS involvement.
Treatment guidelines are lacking in MM with CNS
involvement and particularly the role of B12 deﬁciency in the understanding of MM.
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